EGFR and non-small cell lung carcinoma: Collectively, these results suggest that CIN may activate an innate immune response via the cGAS–STING and downstream inflammatory cytokine and NF-κB signaling pathways in EGFR-mutated NSCLC tumors (Figure 2C).